US 12,433,903 B2
Cannabinoid derivatives and their use
John Crawford, Lexington, KY (US); and Christopher Chengelis, Lexington, KY (US)
Assigned to DEMEETRA AGBIO, INC., Lexington, KY (US)
Filed by Demeetra AgBio, Inc., Lexington, KY (US)
Filed on Apr. 12, 2023, as Appl. No. 18/299,504.
Application 18/299,504 is a continuation of application No. PCT/US2022/074534, filed on Aug. 4, 2022.
Claims priority of provisional application 63/229,442, filed on Aug. 4, 2021.
Prior Publication US 2023/0248748 A1, Aug. 10, 2023
Int. Cl. A61P 1/00 (2006.01); A61K 9/00 (2006.01); A61K 31/00 (2006.01); A61P 1/04 (2006.01); A61P 29/00 (2006.01); C07C 39/19 (2006.01); C07C 43/215 (2006.01); C07C 43/23 (2006.01)
CPC A61K 31/658 (2023.05) [A61K 9/0053 (2013.01); A61P 1/00 (2018.01); A61P 1/04 (2018.01); A61P 29/00 (2018.01); C07C 39/19 (2013.01); C07C 43/215 (2013.01); C07C 43/23 (2013.01)] 8 Claims
 
1. An oral pharmaceutical composition comprising
(i) a cannabinoid compound, wherein the cannabinoid compound consists of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and
(ii) a pharmaceutically acceptable carrier.